Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Clinical trial NCT01586195 · TERMINATED
Trial details
- NCT number
- NCT01586195
- Sponsor
- Genentech, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-10-31
- Primary completion
- 2015-04-30
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.